Beyondspring Inc (NASDAQ:BYSI) – Stock analysts at Seaport Global Securities boosted their Q2 2018 EPS estimates for Beyondspring in a research note issued on Monday, June 25th. Seaport Global Securities analyst V. Bernardino now anticipates that the company will post earnings per share of ($0.65) for the quarter, up from their previous forecast of ($0.66). Seaport Global Securities also issued estimates for Beyondspring’s Q4 2018 earnings at ($0.63) EPS and FY2018 earnings at ($2.55) EPS.
Several other brokerages have also recently weighed in on BYSI. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Beyondspring in a research report on Friday, June 22nd. Maxim Group set a $52.00 price target on shares of Beyondspring and gave the company a “buy” rating in a research report on Monday, March 19th. Zacks Investment Research cut shares of Beyondspring from a “buy” rating to a “hold” rating in a research report on Tuesday, June 5th. Finally, ValuEngine cut shares of Beyondspring from a “hold” rating to a “sell” rating in a research report on Tuesday, May 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $48.80.
Shares of Beyondspring opened at $26.98 on Wednesday, MarketBeat.com reports. The firm has a market capitalization of $608.01 million, a PE ratio of -6.13 and a beta of -0.08. Beyondspring has a 52-week low of $19.55 and a 52-week high of $48.49.
Beyondspring (NASDAQ:BYSI) last announced its quarterly earnings data on Thursday, June 21st. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.73) by $0.12.
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.